GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cryo-Cell International CCEL · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.99

+2.04%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$31.6m

FY2016FY2025

Net income

−$2.4m

FY2016FY2025

Free cash flow

$5.2m

FY2016FY2025

Shareholders' equity

−$18.6m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$31.6m$32.0m$31.3m$30.3m$28.9m$31.1m$31.8m$29.2m$25.4m$23.1m
Gross profit$24.2m$24.0m$22.9m$21.5m$19.9m$21.5m$21.8m$20.7m$18.7m$17.4m
Research and development$376,263$1.2m$1.2m$384,789$49,870$23,851$30,145$91,845$41,165$53,097
Operating income$4.8m$3.5m−$12.3m$4.0m$4.0m$7.7m$5.1m$5.2m$5.0m$433,594
Net income−$2.4m$402,095−$9.5m$2.8m$2.1m$3.6m$2.3m−$854,824$2.3m−$1.3m
Diluted earnings per share-0.300.05-1.140.330.250.480.30-0.110.33-0.19

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$61.7m$64.7m$61.2m$64.9m$60.7m$46.2m$42.9m$42.4m$23.9m$19.5m
Cash and short-term investments$3.3m$3.5m$980,250$1.7m$8.3m$10.4m$7.4m$6.9m$6.7m$4.1m
Total liabilities$80.3m$77.9m$72.3m$66.4m$56.5m$48.9m$49.8m$51.3m$36.4m$35.0m
Debt$11.6m$12.9m$10.9m$11.6m$2.8m$6.2m$9.0m$12.9m$7.3m$9.8m
Shareholders' equity−$18.6m−$13.2m−$11.0m−$1.5m$4.2m−$2.7m−$7.0m−$8.9m−$12.5m−$15.4m
Shares outstanding8m8m8m8m8m8m8m8m7m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$5.5m$6.0m$8.9m$8.6m$7.9m$8.5m$6.3m$5.3m$5.7m$5.0m
Capital spending−$230,475−$3.6m−$7.6m−$17.2m−$7.0m−$449,962−$662,295−$646,163−$98,333−$342,982
Free cash flow$5.2m$2.4m$1.3m−$8.6m$974,923$8.0m$5.7m$4.7m$5.6m$4.6m
Dividends paid−$3.2m−$2.0m—−$7.7m——————

Latest quarters

By quarter end

Aug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024
Revenue$7.8m$7.8m$7.7m$7.8m$7.8m$7.9m$8.0m$8.0m
Gross profit$6.2m$5.9m$6.0m$6.1m$6.0m$6.1m$6.0m$6.4m
Operating income$2.2m$1.2m$765,134−$4.0m$1.9m$1.5m$1.1m−$122,347
Net income$1.3m$554,586$47,108−$4.7m$1.6m$355,785$282,855−$1.9m
Diluted earnings per share0.160.070.01-0.580.200.040.04-0.23
Cash from operations$1.0m$1.0m—$1.0m$2.0m——$2.0m
Total assets$62.3m$60.7m$60.9m$61.7m$63.2m$64.4m$64.4m$64.7m
Cash and short-term investments$4.2m$3.2m$2.9m$3.3m$3.2m$4.4m$3.5m$3.5m
Debt$426,861$8.7m$10.2m$11.1m$3.6m$15.5m$13.5m$12.4m
Shareholders' equity−$16.4m−$17.8m−$18.4m−$18.6m−$14.8m−$15.6m−$14.7m−$13.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.3%0.3%4.1%
Operating income6.4%-8.8%5.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin75.9%74.0%72.4%72.2%
Operating margin13.1%0.0%6.3%9.6%
Net margin-3.2%-7.0%-1.7%2.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-11.4151.3-5.012.946.516.023.5-68.529.7-23.8
Price to sales0.91.91.51.23.41.91.72.02.71.4

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-51%33%32%-65%68%1%-6%-15%110%36%

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 21 May 2025.

FY2025FY2024FY2022
Paid in the year0.400.250.90

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.